Abstract: Provided herein are methods for treating or preventing infection of a subject by a virus that infects the subject through angiotensin converting enzyme 2.

Abstract: The present invention relates to an ACE2 polypeptide lacking an N-linked glycosylation or comprising a truncated N-linked glyco-sylation, e.g., at an amino acid corresponding to Asn90 and/or Asn322 of SEQ ID NO: 1; its use in a treatment of a coronavirus infection and methods of manufacturing the ACE2 polypeptide.

Abstract: A method of generating an artificial blood vessel organoid, including providing stem cells capable of vascular differentiation, stimulating mesoderm differentiation in the stem cells, stimulating vascular differentiation in the stem cells, developing a cell aggregate from the stem cells, embedding the cell aggregates in a collagenous 3D matrix and stimulating vascular differentiation of the aggregate in the collagenous 3D matrix; organoids obtainable from the method, uses of the methods and organoids in manipulation and screening studied and kits for performing the methods.

Abstract: The present disclosure relates to the prevention or treatment of diseases by regulating innate immunity. A Cbl-family inhibitor is provided for use in the prevention or treatment of diseases in a patient, a Cbl-family inhibitor including a binding peptide of Syk, a fusion peptide including a cell delivery portion and a Cbl-family TKB domain binding peptide, wherein the Cbl-family TKB domain binding peptide binds to the TKB domain of a Cbl-family protein, kits and uses for the same.

Abstract: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.

Abstract: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.

Abstract: The present invention relates to uses and methods comprising one or more RANK/RANKL antagonists or of a pharmaceutical composition comprising one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the loss of muscular strength associated with skeletal or cardiac muscle disuse, diseases and aging; or regulating skeletal or cardiac muscle disuse, diseases and/or aging in a patient in need thereof. The present invention also relates to combinations and compositions comprising one or more RANK/RANKL antagonists and to methods for identifying candidate compounds.

Abstract: The present invention relates to uses and methods comprising one or more RANK/RANKL antagonists or of a pharmaceutical composition comprising one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the loss of muscular strength associated with skeletal or cardiac muscle disuse, diseases and aging; or regulating skeletal or cardiac muscle disuse, diseases and/or aging in a patient in need thereof. The present invention also relates to combinations and compositions comprising one or more RANK/RANKL antagonists and to methods for identifying candidate compounds.

Abstract: Apparatus for treating plastic preforms, with a first transport facility transporting the plastic preforms along a predefined transport path at a first predefined pitch, with at least one heating unit heating the plastic preforms at least at times during their transportation and with a second transport facility arranged downstream with respect to the first transport facility in transport direction of the plastic preforms, which comprises a plurality of holding unit means for holding the plastic preforms and which is suitable and destined to alter a pitch between consecutive plastic preforms. The apparatus comprises a further transport section arranged, at least in sections, in transport direction of the plastic preforms between the first transport facility and the second transport facility, in which a pitch between the plastic preforms is altered.

Abstract: The present invention concerns a method of preparing a population of iPS cells comprising reducing the amount and/or activity of one or more components of the CAF1 complex, and/or one or more components of the SUMO pathway, in a population of target cells, and (ii) optionally isolating the iPS cells from the target cell population.

Abstract: The present invention relates to methods and means for detecting cancer or of predicting a patient developing cancer or of determining the rate of progression of cancer in a patient suffering from cancer, comprising determining RANKL activity and/or the amount of OPG in a sample of said patient.

Abstract: In an apparatus for treating plastic preforms, a first transport facility transports the plastic preforms along a predefined transport path at a first predefined pitch, with at least one heating means heating the plastic preforms at least at times during their transportation and with a second transport facility arranged downstream with respect to the first transport facility in transport direction of the plastic preforms, which comprises a plurality of holding means for holding the plastic preforms and which is suitable and destined to alter a pitch between consecutive plastic preforms. According to the invention the apparatus comprises a further transport section arranged, at least in sections, in transport direction of the plastic preforms between the first transport facility and the second transport facility, in which a pitch between the plastic preforms is altered.

Abstract: The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.

Abstract: The present invention relates to the generation of stable haploid cell cultures, uses of said cells in forward and reverse genetics, especially the identification of target genes associated with a modified phenotype and in particular identifying genetic targets associated with toxin resistance, especially ricin toxicity resistance, and therapeutic uses of target compounds.

Abstract: A pharmaceutical composition includes one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier. The composition can be used for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the loss of muscular strength associated with skeletal or cardiac muscle disuse, diseases and aging; or regulating skeletal or cardiac muscle disuse, diseases and/or aging in a patient in need thereof. Methods are used to identify candidate compounds.

Abstract: Washing products comprising a dye transfer inhibitor selected from triazine derivatives of the general formulae T(NH—Ar(SO3Na)a)bHalc (I), X(NH-T(NH—Ar(SO3Na)a)eHalf)2 (II), X(NH-T(NH—Ar(SO3Na)d—NH-T(NH—Ar(SO3Na)a)Hal)Hal)7 (III) and combinations thereof, wherein T represents a 1,3,5-triazinyl; each Ar independently represents a naphthalene or benzene; X represents a divalent hydrocarbyl selected from linear or branched C1-20 hydrocarbon groups optionally including one or more —N(H)— carbon chain interruptions, stilbene and biphenyl groups which may optionally be mono- or poly-SO3Na-substituted; each Hal independently represents a halogen selected chlorine, bromine, and iodine; each of a and d independently represents 1, 2 or 3; b and c each represent 1 or 2 such that b+c=3; e represents 1 or 2 and f represents 0 or 1 such that e+f=2; and wherein the triazinyl substituents are located at the 2, 4 and 6 positions of the 1,3,5-triazinyl.

Abstract: The present invention relates to methods and means for detecting cancer or of predicting a patient developing cancer or of determining the rate of progression of cancer in a patient suffering from cancer, comprising determining RANKL activity and/or the amount of OPG in a sample of said patient.

Abstract: The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.

Abstract: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.

Abstract: A device for molding plastic preforms into plastic containers may include at least one blow station having a first mold part and a second mold part. The first mold part and the second mold part surround a cavity within which the plastic preforms may be expanded into plastic containers. The first mold part may be movable relative to the second mold part. The device includes a first cantilever which is disposed on the first mold part, a second cantilever which is disposed on the second mold part, a first hinge lever which is hingedly connected to the first cantilever, and a second hinge lever which is hingedly connected to the second cantilever. The first cantilever and the second cantilever may be arranged to be pivotable with regard to at least one geometrical pivot axis and may be coupled to an actuating device which causes a movement of the first cantilever and of the second cantilever for moving the mold parts. The blow station may be mounted on a transport via a carrier.